Search Within

Jedd D Wolchok

  1. "2013"
Formats
  1. Meeting Abstract (33)
  2. Journal Article (31)
  3. Book Section (1)
Groups
  1. Department of Medicine (65)
  2. GSK Faculty (65)
  3. Melanoma and Immunotherapeutics Service (65)
  4. Solid Tumor Oncology Division (65)
  5. Melanoma Disease Management Team (14)
  6. Department of Pathology and Laboratory Medicine (12)

More Groups

People
  1. Margaret Callahan (14)
  2. Jianda Yuan (11)
  3. Taha Merghoub (11)
  4. Alan Houghton (10)
  5. Michael Postow (10)
  6. Richard Carvajal (9)

More People

Years
  1. 2013 (65)
Publications
  1. Journal of Clinical Oncology (15)
  2. Journal for ImmunoTherapy of Cancer (6)
  3. Journal of Immunology (5)
  4. Cancer Immunology Research (4)
  5. European Journal of Cancer (4)
  6. Cancer Research (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (15)
  2. American Association for Cancer Research (10)
  3. Elsevier Inc. (8)
  4. Biomed Central Ltd (6)
  5. The American Association of Immunologists, Inc (5)
  6. Springer (4)

More Publishers

Results (65)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
    Meeting Abstract

    Yuan, J.; Zhou, J.; Dong, Z.; Tandon, S.; Kuk, D.; Panageas, K. S.; Wong, P.; Wolchok, J. D.; Hodi, F. S.
    Journal for ImmunoTherapy of Cancer (2013)

    Fulltext@MSK | Save
  • Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment
    Meeting Abstract

    Budhu, S.; Schaer, D.; Li, Y.; Houghton, A.; Silverstein, S.; Merghoub, T.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2013)

    Fulltext@MSK | Save
  • Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
    Meeting Abstract

    Holmgaard, R. B.; Zamarin, D.; Munn, D. H.; Wolchok, J. D.; Allison, J. P.
    Journal for ImmunoTherapy of Cancer (2013)

    Fulltext@MSK | Save
  • Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection
    Meeting Abstract

    Zamarin, D.; Holmgaard, R.; Subudhi, S.; Mansour, M.; Palese, P.; Merghoub, T.; Wolchok, J. D.; Allison, J. P.
    Journal for ImmunoTherapy of Cancer (2013)

    Fulltext@MSK | Save
  • Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
    Meeting Abstract

    Callahan, M. K.; Horak, C. E.; Curran, M. A.; Hollman, T.; Schaer, D. A.; Yuan, J.; Lesokhin, A. M.; Kitano, S.; Hong, Q.; Ariyan, C. E.; more...
    Journal for ImmunoTherapy of Cancer (2013)

    Fulltext@MSK | Save
  • Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
    Meeting Abstract

    Wolchok, J. D.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Reed, K.; Burke, M. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL)
    Meeting Abstract

    Sosman, J. A.; Martin-Algarra, S.; Wolchok, J. D.; Sharfman, W. H.; Bhatia, S.; Hodi, F. S.; Hwu, W. J.; Gajewski, T.; Slingluff, C. L.; Kaufman, H.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody
    Meeting Abstract

    Schindler, K.; Harmankaya, K.; Postow, M. A.; Frantal, S.; Bello, D.; Ariyan, C. E.; Michielin, O. A.; Hoeller, C.; Pehamberger, H.; Wolchok, J. D.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors
    Meeting Abstract

    Sanbom, R. E.; Sharfman, W. H.; Segal, N. H.; Hodi, F. S.; Wolchok, J. D.; Urba, W. J.; Fox, B. A.; Topalian, S. L.; Pardoll, D. M.; Covello, K. L.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Prognostic implication of KIT mutations in melanoma
    Meeting Abstract

    Roth, K. G.; Zabor, E. C.; Colgan, M. N.; Wolchok, J. D.; Chapman, P. B.; Schwartz, G. K.; Panageas, K. S.; Carvajal, R. D.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save